

**TABLE 1. Demographic and Surgical Variables of Patients Valid for Efficacy**

	High-Dose Aprotinin	Low-Dose Aprotinin	Pump-Prime Only	Placebo	Overall <i>P</i> *
Male sex, %	90	88	91	91	.977
White, %	95	92	97	97	.516
Age, y	64±1.0	65±1.0	66±1.0	64±1.0	.267
Weight, kg	85±1.9	85±1.9	84±1.8	86±1.8	.797
Height, mm	1740±11	1730±11	1740±11	1750±11	.645
Mean NYHA functional class (I-IV)	3.3	3.0	3.1	3.1	N/C
Patients with LVEF <50%, n (%)	29/59 (49)	30/59 (51)	42/68 (62)	32/65 (49)	N/C
Patients with ≥ in-situ LIMA/RIMA graft, n (%)	46/61 (75)	38/60 (63)	44/68 (65)	48/65 (74)	.300
Patients with ≥ saphenous-vein graft, n (%)	60/61 (98)	58/60 (97)	66/68 (97)	63/65 (97)	.928
No. of grafts	2.9±0.1	2.5±0.1	2.8±0.1	2.9±0.1	.032
Duration of surgery, h	4.8±0.1 <i>P</i> =.032	4.6±0.2 <i>P</i> =.004	4.9±0.1 <i>P</i> =.098	5.2±0.1	N/C
Closure time, min	58±2.8 <i>P</i> <.001	59±2.9 <i>P</i> <.001	66±2.7 <i>P</i> =.030	74±2.8	N/C

**TABLE 1. Demographic and Surgical Variables of Patients Valid for Efficacy (Cont.)**

	High-Dose Aprotinin	Low-Dose Aprotinin	Pump-Prime Only	Placebo	Overall <i>P</i> *
Heparin during surgery, U	53 400±1500 <i>P</i> =.054	55 800±1600 <i>P</i> =.435	57 000±1500 <i>P</i> =.841	57 400±1500	N/C
Protamine during surgery, U	290±11 <i>P</i> =.094	290±11 <i>P</i> =.139	290±10 <i>P</i> =.046	320±11	N/C
Preoperative hemoglobin, g/dL	13.6±0.2 <i>P</i> =.020	13.7±0.2 <i>P</i> =.063	13.6±0.2 <i>P</i> =.020	14.2±0.2	N/C

NYHA indicates New York Heart Association; LVEF, left ventricular ejection fraction; LIMA/RIMA, left internal mammary artery/right internal mammary artery; and N/C, not calculated.

\*All probability values refer to pairwise comparison of treatment group vs placebo. All ± values are mean±SEM.

Circulation 1995;92:2236-2244

**TABLE 2. Donor-Blood Transfusion Requirement Up To and Including Postoperative Day 12**

	High-Dose Aprotinin N=61	Low-Dose Aprotinin* N=59	Pump-Prime Only N=68	Placebo N=65
Patients requiring donor RBCs, n (%)	33 (54) <i>P</i> = .007	27 (46) <i>P</i> = .001	49 (72) <i>P</i> = .663	49 (75)
Units of donor RBCs transfused, n (median)	1.6±0.2 (1.0) <i>P</i> = .001	1.6±0.3 (0.0) <i>P</i> < .001	2.5±0.3 (2.0) <i>P</i> = .293	3.4±0.5 (3.0)
Patients requiring any donor blood products, n (%)	33 (54) <i>P</i> < .001	31 (53) <i>P</i> < .001	50 (74) <i>P</i> = .125	55 (85)
Units of all blood products transfused, n (median)	2.2±0.4 (1.0) <i>P</i> < .001	3.4±0.9 (1.0) <i>P</i> < .001	5.1±0.9 (2.0) <i>P</i> = .001	10.3±1.4 (6.0)
Platelet units transfused, n (median)	0.5±0.3 (0.0) <i>P</i> < .001	1.2±0.5 (0.0) <i>P</i> < .001	2.1±0.6 (0.0) <i>P</i> < .001	4.8±0.7 (2.0)
Units of fresh frozen plasma transfused, n (median)	0.1±0.0 (0.0) <i>P</i> < .001	0.3±0.1(0.0) <i>P</i> < .001	0.5±0.2 (0.0) <i>P</i> < .001	1.6±0.3 (0.0)
Units of cryoprecipitate transfused, n (median)	0.0±0.0 (0.0) <i>P</i> = .031	0.3±0.2 (0.0) <i>P</i> = .391	0.0±0.2 (0.0) <i>P</i> = .037	0.5±0.2 (0.0)

All probability values refer to pairwise comparison of treatment group vs placebo. All ± values are mean±SEM.

\*Patient suffering from protamine reaction not included in analysis.

**TABLE 3. Postoperative Thoracic Drainage and Mean Decrease in Hemoglobin**

	High-Dose Aprotinin	Low-Dose Aprotinin*	Pump-Prime Only	Placebo
Total thoracic drainage volume, mL	900±136 <i>P</i> <.001	1040±143 <i>P</i> =.001	1420±132 <i>P</i> =.149	1700±140
Rate of drainage in first 6 hours after surgery, mL/h	42±7.6 <i>P</i> <.001	47±7.8 <i>P</i> <.001	67±7.3 <i>P</i> <.001	107±7.4
Hemoglobin decrease (before surgery) to discharge, g/dL	3.1±0.2 <i>P</i> =.002	3.5±0.2 <i>P</i> =.051	3.5±0.2 <i>P</i> =.064	4.1±0.2

\*Patient suffering from protamine reaction not included in analysis.

All probability values refer to pairwise comparison of treatment group vs placebo. All ± values are mean±SEM.

Circulation 1995;92:2236-2244

**TABLE 4. Incidence of MI as Evaluated on a Blinded Basis**

	<b>Aprotinin High-Dose</b>	<b>Aprotinin Low-Dose</b>	<b>Pump-Prime Only</b>	<b>Placebo</b>
Definite: ECG data, n (%)	8/68 (12) <i>P</i> =.856	10/68 (15) <i>P</i> =.629	6/70 (9) <i>P</i> =.331	8/67 (12)
Definite or probable: all data, n (%)	20/70 (29) <i>P</i> =.973	20/67 (30) <i>P</i> =.744	16/68 (24) <i>P</i> =.403	19/65 (29)
Definite, probable, or possible: all data, n (%)	23/71 (32) <i>P</i> =.819	22/69 (32) <i>P</i> =.707	17/70 (24) <i>P</i> =.329	21/67 (31)
No MI: all data, n (%)	48/71 (68) <i>P</i> =.819	47/69 (68) <i>P</i> =.707	53/70 (76) <i>P</i> =.329	46/67 (69)

Circulation 1995;92:2236-2244

**TABLE 5. Laboratory Indexes of Kidney Function**

	High-dose Aprotinin	Low-Dose Aprotinin	Pump-Prime Only	Placebo	Overall <i>P</i>
Serum creatinine					
≥ 44.2 μmol/L (0.5 mg/dL) over baseline, n (%)	12/70 (17%)	12/68 (128%)	16/72 (22%)	14/71 (20%)	.866
≥ 176.8 μmol/L (2.0 mg/dL) over baseline, n (%)	1/70 (1%)	2/68 (3%)	2/72 (3%)	2/71 (3%)	.959
Serum potassium					
Postbaseline value ≥ 5.5 mEq/L, n (%)	6/71 (8%)	4/69 (6%)	1/72 (1%)	5/69 (7%)	.285

Circulation 1995;92:2236-2244